18 patents currently held
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2033. from the record
Of the 7 now held by other companies, 4 name Mayne Pharma LLC as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2033
Next term end
11
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2038 · High confidence
Also notable
Ends Jan 2036 · High confidence
Also notable
Ends Aug 2039 · High confidence
Also notable
Ends Nov 2041 · High confidence
Also notable
Ends Jan 2042 · High confidence
Also notable
Ends Jun 2034 · High confidence
Also notable
Ends Aug 2033 · High confidence
Also notable
Ends Jan 2035 · High confidence
Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same
US 10,981,906
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
Heterocyclic Itk Inhibitors for Treating Inflammation and Cancer
US 10,150,783
Granted 2018. Computed term ends 2036.
Pyrrolopyrimidine Itk Inhibitors
US 11,021,482
Granted 2021. Computed term ends 2039.
Methods of Synthesizing Substituted Pyridinone-Pyridinyl Compounds
US 11,767,309
Cited by 5 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041.
Oral Compositions of MK2 Pathway Inhibitor for Treatment of Immune Conditions
US 11,844,801
Granted 2023. Computed term ends 2042.
Methyl/Fluoro-Pyridinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds and Fluoro-Pyrimidinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds
US 9,636,333
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Substituted Pyrimidinone-Phenyl-Pyrimidinyl Compounds
US 9,056,110
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2033.
Arylpyridinone Itk Inhibitors for Treating Inflammation and Cancer
US 9,145,393
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2035.
Formerly held, still cited
Notable
Ends Dec 2031 · High confidence
The most cited patent in this portfolio, cited by 119 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2031.
now held by Epi Health, LLC
Also notable
Ends Jun 2035 · Medium confidence
Cited by 19 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
now held by Mayne Pharma LLC
Also notable
Ends Oct 2029 · High confidence
Cited by 43 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
now held by Epi Health, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 11 to 16, 2026 · next Dec 11
- 2 fees due Feb 25 to 28, 2027 · next Feb 25
- 2 fees due Mar 26 to 29, 2027 · next Mar 26
- 1 fee due May 21, 2027The maintenance fee for Pyrrolopyrimidine Itk Inhibitors (US 11,820,775) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Oral Compositions of MK2 Pathway Inhibitor for Treatment of Immune Conditions (US 11,844,801) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
Recent changes
- Nov 9Assignment recorded on 1 record: Decrescenzo, Gary A. and 2 others to Aclaris Therapeutics, Inc. Recorded Nov 9, 2026, executed Feb 7, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 137.
- Nov 9Assignment recorded on 1 record: Decrescenzo, Gary A. and 2 others to Aclaris Therapeutics, Inc. Recorded Nov 9, 2026, executed Jul 29, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 480.
- 1 term has ended since Aug 23, 2026
- Aug 23 US 11,420,966 Substituted Pyrrolopyridines as Jak Inhibitors · lapsed on the fee record
What they patent
The largest of its 11 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,056,110 | Substituted Pyrimidinone-Phenyl-Pyrimidinyl Compounds In force · High confidence | In force | High confidence | |
| US 9,115,089 | Methyl/Fluoro-Pyridinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds and Fluoro-Pyrimidinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds In force · High confidence | In force | High confidence | |
| US 9,636,333 | Methyl/Fluoro-Pyridinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds and Fluoro-Pyrimidinyl-Methoxy Substituted Pyridinone-Pyridinyl Compounds In force · High confidence | In force | High confidence | |
| US 9,145,393 | Arylpyridinone Itk Inhibitors for Treating Inflammation and Cancer In force · High confidence | In force | High confidence | |
| US 10,150,783 | Heterocyclic Itk Inhibitors for Treating Inflammation and Cancer In force · High confidence | In force | High confidence | |
| US 10,316,038 | Pyrrolopyrimidine Itk Inhibitors for Treating Inflammation and Cancer In force · High confidence | In force | High confidence | |
| US 10,981,906 | Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 11,739,086 | Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 12,281,111 | Substituted Pyrrolopyridine Jak Inhibitors and Methods of Making and Using the Same In force · High confidence | In force | High confidence | |
| US 11,021,482 | Pyrrolopyrimidine Itk Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 7 patents in force now held by others · 19 patents ended · 10 applications pending · 16 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.